BioPharmSignal logoBioPharmSignal

Biotech News

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion (BMEA)Biomea FusionEarnings

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date Topline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1

Open original release

Related news

BMEABiomea Fusion2026-06-03 12:00 EST

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

BMEABiomea Fusion2026-05-05 21:51 EST

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

GERNGeron2026-05-06 11:00 EST

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

COGTCogent Biosciences2026-05-05 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

RVMDRevolution Medicines2026-05-06 20:02 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

EXELExelixis2026-05-05 20:05 EST

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

LEGNLegend Biotech Corporation2026-05-12 11:00 EST

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

View all latest news

Biomea Fusion

Biomea Fusion is a metabolic-disease and oncology biotech built around covalent inhibitor chemistry. Its pipeline is focused on diseases where precision small-molecule design can matter.

Recent company news

BMEABiomea Fusion2026-06-03 12:00 EST

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

BMEABiomea Fusion2026-05-05 21:51 EST

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

BMEABiomea Fusion2026-04-27 21:37 EST

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

BMEABiomea Fusion2026-03-31 11:00 EST

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Stock data

Close
1.26 USD
Market cap
99.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States